Vaxiion
is dedicated to the design and development of intelligent drug-delivery
technologies with special emphasis on targeted oncology therapeutics. Vaxiion's
current focus is the development of a programmable—and therefore
intelligent—platform capable of delivering chemotherapeutic drugs directly
to cancer cells, thereby improving efficacy while reducing the toxic side
effects associated with current chemotherapy treatment regimes. Underlying this
platform is the use of genetically engineered non-living bacterial minicells
that provide a multitude of comparative advantages over alternative bacterial
and liposomal drug-delivery systems. Vaxiion's proprietary
minicell-based drug delivery system, which is protected by a robust
intellectual property estate, has shown compelling efficacy in preclinical
animal models.

"Intelligent design of targeted delivery products"
Another Western States Investment Group Portfolio Company